rs10968749 - LINGO2

Magnitude 2.2 · 1 study on file

Reported associations

  • Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs. - Journal of psychopharmacology (Oxford, England) (2016) · Athanasiu L, Smorr LL, Tesli M, Røssberg JI, Sønderby IE, Spigset O, Djurovic S, Andreassen OA · PubMed 25944848

    Individual variation in pharmacokinetics of psychotropic drugs, particularly metabolism, is an important factor to consider in pharmacological treatment in psychiatry. A large proportion of this variance is still not accounted for, but evidence so far suggests the involvement of genetic factors. We performed a genome-wide association study (GWAS) with concentration dose ratio (CDR) as sub-phenotype to assess metabolism rate of psychotropic drugs in a homogenous Norwegian sample of 1334 individuals diagnosed with a severe mental disorder. The GWAS revealed one genome-wide significant marker (rs16935279, p-value=3.95×10(-10), pperm=7.5×10(-4)) located in an intronic region of the lncRNA LOC100505718. Carriers of the minor allele have a lower metabolism rate of antiepileptic drugs compared


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • LINGO2 variant impact on olanzapine metabolism Moderate

    LINGO2 rs10968749 G allele increases olanzapine concentration-dose ratio in severe mental disorder patients

    If on olanzapine, request serum concentration monitoring or dose adjustment based on LINGO2 genotype